| Literature DB >> 30015454 |
Magdalena Zalewska1,2, John J Churey3, Randy W Worobo2, Sławomir Milewski1, Piotr Szweda1.
Abstract
A collection of 206 Staphylococcus spp. isolates was investigated for their ability to produce compounds exhibiting antistaphylococcal activity. This group included Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus xylosus strains recovered from bovine mastitis (n = 158) and human skin wounds and soft tissues infections (n = 48). Production of substances with antimicrobial activity was observed in six strains. Five of them were recovered from bovine mastitis, and one was isolated from the infected human skin wound. Three of the six antimicrobials produced by the different strains showed substantial loss of antimicrobial activity upon treatment with proteolytic enzymes, which suggests their peptidic structure. Additional studies have shown that one of the putative bacteriocins was efficiently secreted to the liquid medium, facilitating its large-scale production and isolation. The peptide produced by the M2B strain exhibited promising activity; however, against narrow spectrum of Staphylococcus spp. clinical and animal isolates. Growth inhibition was observed only in the case of 13 (including nine S. aureus, three S. xylosus and one S. epidermidis strains) out of 206 strains tested. Important advantage of the produced agent was its high thermal stability. Fifteen minutes of incubation at 90°C did not affect its antimicrobial potential. The highest efficiency of production of the agent was demonstrated in TSB medium after 24 hours at 37°C. The researches revealed that ability to production of bacteriocin among staphylococci is not very common. Only one (S. xylosus strain assigned as M2B) out of 206 strains tested produced satisfactory amounts of antistaphylococcal bacteriocin. In spite of that, we would encourage other researchers for investigation of their collections of Staphylococcus spp. isolates towards selection strains producing antimicrobial agents.Entities:
Keywords: Staphylococcus; Staphylococcus aureus; Staphylococcus xylosus; antimicrobial peptides; antistaphylococcal agents
Mesh:
Substances:
Year: 2018 PMID: 30015454 PMCID: PMC7256840 DOI: 10.21307/pjm-2018-018
Source DB: PubMed Journal: Pol J Microbiol ISSN: 1733-1331
The indicator strains used for preliminary selections of staphylococci producing antibacterial agents.
| Strain | Source of the strain | Resistance |
|---|---|---|
| 1 | Bovine mastitis | ND |
| 2 | Bovine mastitis | ND |
| 3 | Human skin wound (Koszalin) | Susceptible |
| 4 | Bovine mastitis | P, AMP, AML, S, AMC[ |
| 5 | Bovine mastitis | N, MY, S, E, DA[ |
| 6 | Bovine mastitis | P+DA+E+MY+S+N/OX[ |
| 7 | Reference strain | ND |
– Resistance according to
Fig. 1.Growth inhibition zone around the colony of producer strain M2B; an indicator strain – S. aureus 30C1.
Fig. 2.Formation of “half moon zone” near the colony of producer strain M2B in the presence of proteolytic enzyme; an indicator strain – L. monocytogenes.
Fig. 3.Antimicrobial activity of the after-culture liquid media after growth of the producer strain.
Activity of newly identified agent against strains from the Departments’ collection.
| No. of strain | Code number of the sensitive strain | Growth inhibition zone [mm] |
|---|---|---|
| 1 | 7 ( | 12 |
| 2 | 11 ( | 20 |
| 3 | 28 ( | 15 |
| 4 | 52 ( | 22 |
| 5 | 68 ( | 25 |
| 6 | 77 ( | 18 |
| 7 | 92 ( | 17 |
| 8 | 99 ( | 25 |
| 9 | 115 ( | 15 |
| 10 | 83A ( | 15 |
| 11 | 8J ( | 15 |
| 12 | 30C1 ( | 15 |
| 13 | 247 ( | 15 |
| 14 | 15 | |
| 15 | 15 |